Clinical Trial Update: Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of brentuximab vedotin and nivolumab for relapsed/refractory classical Hodgkin lymphoma; currently recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classical Hodgkin Lymphoma

Drugs mentioned

• Adcetris (Brentuximab vedotin)
• OPDIVO (nivolumab)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Relapsed Classic Hodgkin Lymphoma | Phase 2 | Status: RECRUITING